speb/financial-data huggingface dataset:
SYR.AX balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 187000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Current Debt: 160079000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Current Debt: 160079000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 160266000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 160266000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 118000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 118000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Current Deferred Taxes Liabilities: 118000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Current Deferred Taxes Liabilities: 118000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Current Liabilities: 187787000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 187787000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Current Provisions: 1007000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Current Provisions: 1007000.00
SYR.AX income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 20655000.00
SYR.AX income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 20655000.00
SYR.AX income_statement (annual, 2025-12-31) — Depreciation Income Statement: 20655000.00
SYR.AX income_statement (annual, 2025-12-31) — Diluted Average Shares: 1298899154.00
SYR.AX income_statement (annual, 2025-12-31) — Diluted EPS: -0.08
SYR.AX income_statement (annual, 2025-12-31) — EBIT: -62045000.00
SYR.AX income_statement (annual, 2025-12-31) — EBITDA: -41390000.00
SYR.AX cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 1119000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Employee Benefits: 107000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Employee Benefits: 107000.00
SYR.AX cash_flow (annual, 2025-12-31) — End Cash Position: 77087000.00
SYR.AX cash_flow (annual, 2025-12-31) — Financing Cash Flow: 50677000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Finished Goods: 6466000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Finished Goods: 6466000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Foreign Currency Translation Adjustments: -24629000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Foreign Currency Translation Adjustments: -24629000.00
SYR.AX cash_flow (annual, 2025-12-31) — Free Cash Flow: -62176000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -12650000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -12650000.00
SYR.AX income_statement (annual, 2025-12-31) — General And Administrative Expense: 11340000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 8000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 8000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Gross PPE: 608790000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Gross PPE: 608790000.00
SYR.AX income_statement (annual, 2025-12-31) — Gross Profit: -44873000.00
SYR.AX cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: -11696000.00
SYR.AX income_statement (annual, 2025-12-31) — Interest Expense: 37646000.00
SYR.AX income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 37646000.00
SYR.AX income_statement (annual, 2025-12-31) — Interest Income: 2233000.00
SYR.AX income_statement (annual, 2025-12-31) — Interest Income Non Operating: 2233000.00
SYR.AX cash_flow (annual, 2025-12-31) — Interest Received Direct: 2233000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Inventory: 29038000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Inventory: 29038000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Invested Capital: 622083000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Invested Capital: 622083000.00
SYR.AX cash_flow (annual, 2025-12-31) — Investing Cash Flow: -5814000.00
SYR.AX cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 45524000.00
SYR.AX cash_flow (annual, 2025-12-31) — Issuance Of Debt: 17038000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Land And Improvements: 115459000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 115459000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 211000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 211000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Long Term Debt: 132757000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 132757000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 132968000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 132968000.00
SYR.AX cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 17038000.00
SYR.AX cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -9350000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Long Term Provisions: 13119000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Long Term Provisions: 13119000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 355402000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 355402000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Minority Interest: -3506000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Minority Interest: -3506000.00
SYR.AX cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 43793000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Net Debt: 215749000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Net Debt: 215749000.00
SYR.AX income_statement (annual, 2025-12-31) — Net Income: -100663000.00
SYR.AX income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -100663000.00
SYR.AX income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -100663000.00
SYR.AX income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -100663000.00
SYR.AX income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -100663000.00
SYR.AX income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -100663000.00
SYR.AX income_statement (annual, 2025-12-31) — Net Interest Income: -35413000.00
SYR.AX cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 7688000.00
SYR.AX cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 7688000.00
SYR.AX income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -35413000.00
SYR.AX cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -804000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Net PPE: 509390000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Net PPE: 509390000.00
SYR.AX cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -5814000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 329239000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 329239000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Non Current Accounts Receivable: 9322000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Non Current Accounts Receivable: 9322000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 67236000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 67236000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 47437000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 47437000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 67236000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 67236000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 47437000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 47437000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 107000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 107000.00
SYR.AX income_statement (annual, 2025-12-31) — Normalized EBITDA: -41390000.00
SYR.AX income_statement (annual, 2025-12-31) — Normalized Income: -100663000.00
SYR.AX income_statement (annual, 2025-12-31) — Operating Income: -86450000.00
SYR.AX income_statement (annual, 2025-12-31) — Operating Revenue: 33381000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 1488534520.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 1488534520.00
SYR.AX balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 160079000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 160079000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 11979000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 11979000.00
SYR.AX income_statement (annual, 2025-12-31) — Other Gand A: 2218000.00
SYR.AX income_statement (annual, 2025-12-31) — Other Income Expense: 22172000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 8000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 8000.00
SYR.AX income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 22172000.00
SYR.AX income_statement (annual, 2025-12-31) — Other Operating Expenses: 2583000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Other Payable: 2851000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Other Payable: 2851000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Other Properties: 690000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Other Properties: 690000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Other Receivables: 8951000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Other Receivables: 8951000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Payables: 25004000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Payables: 25004000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 25004000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 25004000.00
SYR.AX cash_flow (annual, 2025-12-31) — Paymentsto Suppliersfor Goodsand Services: -98650000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 1392000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 1392000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Prepaid Assets: 2699000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 2699000.00
SYR.AX income_statement (annual, 2025-12-31) — Pretax Income: -99691000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Properties: 112218000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Properties: 112218000.00
SYR.AX cash_flow (annual, 2025-12-31) — Purchase Of PPE: -5814000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Raw Materials: 22210000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Raw Materials: 22210000.00
SYR.AX cash_flow (annual, 2025-12-31) — Receiptsfrom Customers: 28359000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Receivables: 16405000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Receivables: 16405000.00
SYR.AX income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 78254000.00
SYR.AX income_statement (annual, 2025-12-31) — Reconciled Depreciation: 20655000.00
SYR.AX cash_flow (annual, 2025-12-31) — Repayment Of Debt: -9350000.00
SYR.AX cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -1731000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Retained Earnings: -643956000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -643956000.00
SYR.AX income_statement (annual, 2025-12-31) — Salaries And Wages: 9122000.00
SYR.AX income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 6999000.00
SYR.AX income_statement (annual, 2025-12-31) — Selling General And Administration: 18339000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Share Issued: 1488534520.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Share Issued: 1488534520.00
SYR.AX balance_sheet (annual, 2025-12-31) — Stockholders Equity: 329247000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 329247000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Tangible Book Value: 329239000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 329239000.00
SYR.AX income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
SYR.AX income_statement (annual, 2025-12-31) — Tax Provision: 972000.00
SYR.AX income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.30
SYR.AX cash_flow (annual, 2025-12-31) — Taxes Refund Paid Direct: 11696000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Total Assets: 711185000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Total Assets: 711185000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Total Capitalization: 462004000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 462004000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Total Debt: 293234000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Total Debt: 293234000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 325741000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 325741000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 385444000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 385444000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 585956000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 585956000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 197657000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 197657000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Tradeand Other Payables Non Current: 4026000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Tradeand Other Payables Non Current: 4026000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Work In Process: 362000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Work In Process: 362000.00
SYR.AX balance_sheet (annual, 2025-12-31) — Working Capital: -62558000.00
SYR.AX balance_sheet (quarterly, 2025-12-31) — Working Capital: -62558000.00
SYRE balance_sheet (annual, 2021-12-31) — Accumulated Depreciation: -2802000.00
SYRE cash_flow (annual, 2021-12-31) — Capital Expenditure: -573000.00
SYRE balance_sheet (annual, 2021-12-31) — Capital Lease Obligations: 5060000.00
SYRE cash_flow (annual, 2021-12-31) — Change In Other Working Capital: 3576000.00
SYRE balance_sheet (annual, 2021-12-31) — Current Capital Lease Obligation: 436000.00
SYRE balance_sheet (annual, 2021-12-31) — Current Debt And Capital Lease Obligation: 436000.00
SYRE balance_sheet (annual, 2021-12-31) — Current Deferred Liabilities: 2359000.00
SYRE balance_sheet (annual, 2021-12-31) — Current Deferred Revenue: 2359000.00
SYRE cash_flow (annual, 2021-12-31) — Gain Loss On Investment Securities: -344000.00
SYRE balance_sheet (annual, 2021-12-31) — Gross PPE: 11157000.00
SYRE balance_sheet (annual, 2021-12-31) — Leases: 4393000.00
SYRE balance_sheet (annual, 2021-12-31) — Long Term Capital Lease Obligation: 4624000.00
SYRE balance_sheet (annual, 2021-12-31) — Long Term Debt And Capital Lease Obligation: 4624000.00
SYRE cash_flow (annual, 2021-12-31) — Long Term Debt Payments: -510000.00
SYRE balance_sheet (annual, 2021-12-31) — Machinery Furniture Equipment: 713000.00
SYRE income_statement (annual, 2021-12-31) — Net Income: -65801000.00
SYRE cash_flow (annual, 2021-12-31) — Net Intangibles Purchase And Sale: 0.00
SYRE cash_flow (annual, 2021-12-31) — Net Issuance Payments Of Debt: -510000.00
SYRE cash_flow (annual, 2021-12-31) — Net Long Term Debt Issuance: -510000.00
SYRE balance_sheet (annual, 2021-12-31) — Net PPE: 8355000.00
SYRE balance_sheet (annual, 2021-12-31) — Non Current Deferred Liabilities: 1217000.00
SYRE balance_sheet (annual, 2021-12-31) — Non Current Deferred Revenue: 1217000.00
SYRE cash_flow (annual, 2021-12-31) — Operating Gains Losses: -344000.00
SYRE balance_sheet (annual, 2021-12-31) — Other Non Current Assets: 2680000.00
SYRE balance_sheet (annual, 2021-12-31) — Other Properties: 6051000.00
SYRE balance_sheet (annual, 2021-12-31) — Other Receivables: 815000.00
SYRE balance_sheet (annual, 2021-12-31) — Prepaid Assets: 4948000.00
SYRE balance_sheet (annual, 2021-12-31) — Properties: 0.00
SYRE cash_flow (annual, 2021-12-31) — Purchase Of PPE: -573000.00
SYRE balance_sheet (annual, 2021-12-31) — Receivables: 815000.00
SYRE cash_flow (annual, 2021-12-31) — Repayment Of Debt: -510000.00
SYRE balance_sheet (annual, 2021-12-31) — Total Debt: 5060000.00
SYRE income_statement (annual, 2022-12-31) — +Operating Expense: 87110000.00
SYRE income_statement (annual, 2022-12-31) — +Total Revenue: 503132.43
SYRE balance_sheet (annual, 2022-12-31) — Accounts Payable: 677000.00
SYRE balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -4144000.00
SYRE balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 475971000.00
SYRE cash_flow (annual, 2022-12-31) — Amortization Of Securities: -327000.00
SYRE cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 0.00
SYRE income_statement (annual, 2022-12-31) — Basic Average Shares: 3371231.00
SYRE income_statement (annual, 2022-12-31) — Basic EPS: -24.75
SYRE cash_flow (annual, 2022-12-31) — Beginning Cash Position: 16980000.00
SYRE cash_flow (annual, 2022-12-31) — Capital Expenditure: -38000.00
SYRE balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 4629000.00
SYRE balance_sheet (annual, 2022-12-31) — Capital Stock: 6000.00
SYRE balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 34863000.00
SYRE balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 55711000.00
SYRE cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 42678000.00
SYRE cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: 57008000.00
SYRE cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -80144000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Account Payable: -2641000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -843000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -435000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -880000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Payable: -2641000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -3484000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -1144000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Receivables: 440000.00
SYRE cash_flow (annual, 2022-12-31) — Change In Working Capital: -5503000.00
SYRE cash_flow (annual, 2022-12-31) — Changes In Cash: 19542000.00
SYRE balance_sheet (annual, 2022-12-31) — Common Stock: 6000.00
SYRE balance_sheet (annual, 2022-12-31) — Common Stock Equity: 50305000.00
SYRE cash_flow (annual, 2022-12-31) — Common Stock Issuance: 42874000.00
SYRE balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 7918000.00
SYRE balance_sheet (annual, 2022-12-31) — Current Assets: 62258000.00
SYRE balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 625000.00
SYRE balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 625000.00
SYRE balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 517000.00
SYRE balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 517000.00
SYRE balance_sheet (annual, 2022-12-31) — Current Liabilities: 14656000.00
SYRE cash_flow (annual, 2022-12-31) — Depreciation: 1964000.00
SYRE cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 1964000.00
SYRE cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 1964000.00
SYRE income_statement (annual, 2022-12-31) — Diluted Average Shares: 3371231.00
SYRE income_statement (annual, 2022-12-31) — Diluted EPS: -24.75
SYRE income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -83815000.00
SYRE balance_sheet (annual, 2022-12-31) — Dueto Related Parties Current: 0.00
SYRE income_statement (annual, 2022-12-31) — EBIT: -84781000.00
SYRE income_statement (annual, 2022-12-31) — EBITDA: -82817000.00
SYRE cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -106000.00
SYRE cash_flow (annual, 2022-12-31) — End Cash Position: 36416000.00
SYRE cash_flow (annual, 2022-12-31) — Financing Cash Flow: 42678000.00
SYRE cash_flow (annual, 2022-12-31) — Free Cash Flow: -80182000.00
SYRE cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: 428000.00
SYRE cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 0.00
SYRE income_statement (annual, 2022-12-31) — Gain On Sale Of Ppe: 0.00
SYRE balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -48000.00
SYRE income_statement (annual, 2022-12-31) — General And Administrative Expense: 28531000.00
SYRE balance_sheet (annual, 2022-12-31) — Gross PPE: 10794000.00
SYRE income_statement (annual, 2022-12-31) — Interest Income: 837000.00
SYRE income_statement (annual, 2022-12-31) — Interest Income Non Operating: 837000.00
SYRE cash_flow (annual, 2022-12-31) — Interest Received Cfo: 0.00
SYRE balance_sheet (annual, 2022-12-31) — Invested Capital: 50305000.00
SYRE cash_flow (annual, 2022-12-31) — Investing Cash Flow: 57008000.00
SYRE cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 42874000.00
SYRE balance_sheet (annual, 2022-12-31) — Leases: 4393000.00
SYRE balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 4004000.00
SYRE balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 4004000.00
SYRE cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -418000.00
SYRE balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 714000.00
SYRE cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 0.00
SYRE cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 42874000.00
SYRE income_statement (annual, 2022-12-31) — Net Income: -83815000.00
SYRE income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -83815000.00
SYRE income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -83815000.00
SYRE income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -83815000.00
SYRE income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -83815000.00
SYRE cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -83815000.00
SYRE income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -83815000.00
SYRE cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: 0.00
SYRE income_statement (annual, 2022-12-31) — Net Interest Income: 837000.00
SYRE cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: 57046000.00
SYRE cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -418000.00
SYRE cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -418000.00
SYRE income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 837000.00
SYRE balance_sheet (annual, 2022-12-31) — Net PPE: 6650000.00
SYRE cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -38000.00
SYRE cash_flow (annual, 2022-12-31) — Net Preferred Stock Issuance: 0.00
SYRE balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 50305000.00
SYRE balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 2179000.00
SYRE balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 2179000.00
SYRE income_statement (annual, 2022-12-31) — Normalized EBITDA: -82817000.00
SYRE income_statement (annual, 2022-12-31) — Normalized Income: -83815000.00
SYRE cash_flow (annual, 2022-12-31) — Operating Cash Flow: -80144000.00
SYRE cash_flow (annual, 2022-12-31) — Operating Gains Losses: 428000.00
SYRE income_statement (annual, 2022-12-31) — Operating Income: -84781000.00
SYRE income_statement (annual, 2022-12-31) — Operating Revenue: 503132.43
SYRE balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 2614013.00
SYRE balance_sheet (annual, 2022-12-31) — Other Current Assets: 6172000.00
SYRE balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 330000.00
SYRE balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -48000.00
SYRE income_statement (annual, 2022-12-31) — Other Gand A: 28531000.00
SYRE income_statement (annual, 2022-12-31) — Other Income Expense: -7000.00
SYRE cash_flow (annual, 2022-12-31) — Other Non Cash Items: 426000.00
SYRE balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 2236000.00
SYRE income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: -7000.00
SYRE balance_sheet (annual, 2022-12-31) — Other Properties: 5687000.00
SYRE balance_sheet (annual, 2022-12-31) — Other Receivables: 375000.00
SYRE balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 20848000.00
SYRE balance_sheet (annual, 2022-12-31) — Payables: 677000.00
SYRE balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 8595000.00
SYRE balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 4589000.00
SYRE balance_sheet (annual, 2022-12-31) — Preferred Securities Outside Stock Equity: 0.00
SYRE balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
SYRE cash_flow (annual, 2022-12-31) — Preferred Stock Issuance: 0.00
SYRE income_statement (annual, 2022-12-31) — Pretax Income: -83951000.00
SYRE cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 222000.00
SYRE balance_sheet (annual, 2022-12-31) — Properties: 0.00
SYRE cash_flow (annual, 2022-12-31) — Purchase Of Investment: -39500000.00
SYRE cash_flow (annual, 2022-12-31) — Purchase Of PPE: -38000.00
SYRE balance_sheet (annual, 2022-12-31) — Receivables: 375000.00
SYRE income_statement (annual, 2022-12-31) — Reconciled Depreciation: 1964000.00
SYRE cash_flow (annual, 2022-12-31) — Repayment Of Debt: -418000.00
SYRE income_statement (annual, 2022-12-31) — Research And Development: 58579000.00
SYRE balance_sheet (annual, 2022-12-31) — Retained Earnings: -425624000.00
SYRE cash_flow (annual, 2022-12-31) — Sale Of Business: 0.00
SYRE cash_flow (annual, 2022-12-31) — Sale Of Intangibles: 0.00
SYRE cash_flow (annual, 2022-12-31) — Sale Of Investment: 96546000.00
SYRE cash_flow (annual, 2022-12-31) — Sale Of PPE: 0.00
SYRE income_statement (annual, 2022-12-31) — Selling General And Administration: 28531000.00
SYRE balance_sheet (annual, 2022-12-31) — Share Issued: 2614013.00
SYRE income_statement (annual, 2022-12-31) — Special Income Charges: 0.00
SYRE cash_flow (annual, 2022-12-31) — Stock Based Compensation: 7111000.00
SYRE balance_sheet (annual, 2022-12-31) — Stockholders Equity: 50305000.00
SYRE balance_sheet (annual, 2022-12-31) — Tangible Book Value: 50305000.00
SYRE income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
SYRE income_statement (annual, 2022-12-31) — Tax Provision: -136000.00
SYRE income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
SYRE balance_sheet (annual, 2022-12-31) — Total Assets: 71144000.00
SYRE balance_sheet (annual, 2022-12-31) — Total Capitalization: 50305000.00
SYRE balance_sheet (annual, 2022-12-31) — Total Debt: 4629000.00
SYRE balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 50305000.00
SYRE income_statement (annual, 2022-12-31) — Total Expenses: 87110000.00
SYRE balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 20839000.00
SYRE balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 8886000.00
SYRE balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 6183000.00
SYRE income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -84781000.00
SYRE income_statement (annual, 2022-12-31) — Total Unusual Items: 0.00
SYRE income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 0.00
SYRE balance_sheet (annual, 2022-12-31) — Working Capital: 47602000.00
SYRE income_statement (annual, 2023-12-31) — +Operating Expense: 129450000.00
SYRE income_statement (annual, 2023-12-31) — +Total Revenue: 886000.00
SYRE balance_sheet (annual, 2023-12-31) — Accounts Payable: 896000.00
SYRE balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 763191000.00
SYRE cash_flow (annual, 2023-12-31) — Amortization Of Securities: -2318000.00
SYRE cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 2580000.00
SYRE income_statement (annual, 2023-12-31) — Basic Average Shares: 6897065.00
SYRE income_statement (annual, 2023-12-31) — Basic EPS: -13.76
SYRE cash_flow (annual, 2023-12-31) — Beginning Cash Position: 36416000.00
SYRE balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Capital Stock: 184937000.00
SYRE balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 188893000.00
SYRE balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 339277000.00
SYRE cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 361077000.00
SYRE cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -108393000.00
SYRE cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -99910000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Account Payable: -2184000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Accrued Expense: -4891000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -2326000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Other Working Capital: 575000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Payable: -2184000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: -7075000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 3245000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Receivables: 375000.00
SYRE cash_flow (annual, 2023-12-31) — Change In Working Capital: -5206000.00
SYRE cash_flow (annual, 2023-12-31) — Changes In Cash: 152774000.00
SYRE balance_sheet (annual, 2023-12-31) — Common Stock: 10000.00
SYRE balance_sheet (annual, 2023-12-31) — Common Stock Equity: -911000.00
SYRE cash_flow (annual, 2023-12-31) — Common Stock Issuance: 84555000.00
SYRE balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 8566000.00
SYRE balance_sheet (annual, 2023-12-31) — Current Assets: 341528000.00
SYRE balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Current Liabilities: 31978000.00
SYRE cash_flow (annual, 2023-12-31) — Depreciation: 744000.00
SYRE cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 744000.00
SYRE cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 744000.00
SYRE income_statement (annual, 2023-12-31) — Diluted Average Shares: 6897065.00
SYRE income_statement (annual, 2023-12-31) — Diluted EPS: -13.76
SYRE income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -338790000.00
SYRE balance_sheet (annual, 2023-12-31) — Dueto Related Parties Current: 16584000.00
SYRE income_statement (annual, 2023-12-31) — EBIT: -128564000.00
SYRE income_statement (annual, 2023-12-31) — EBITDA: -127820000.00
SYRE cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 25000.00
SYRE cash_flow (annual, 2023-12-31) — End Cash Position: 189215000.00
SYRE cash_flow (annual, 2023-12-31) — Financing Cash Flow: 361077000.00
SYRE cash_flow (annual, 2023-12-31) — Free Cash Flow: -99910000.00
SYRE cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: 83530000.00
SYRE cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: 114654000.00
SYRE income_statement (annual, 2023-12-31) — Gain On Sale Of Ppe: 16449000.00
SYRE income_statement (annual, 2023-12-31) — Gain On Sale Of Security: -83530000.00
SYRE balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 302000.00
SYRE income_statement (annual, 2023-12-31) — General And Administrative Expense: 39946000.00
SYRE balance_sheet (annual, 2023-12-31) — Gross PPE: 0.00
SYRE income_statement (annual, 2023-12-31) — Interest Income: 6147000.00
SYRE income_statement (annual, 2023-12-31) — Interest Income Non Operating: 6147000.00
SYRE cash_flow (annual, 2023-12-31) — Interest Received Cfo: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Invested Capital: -911000.00
SYRE cash_flow (annual, 2023-12-31) — Investing Cash Flow: -108393000.00
SYRE cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 366474000.00
SYRE balance_sheet (annual, 2023-12-31) — Leases: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 0.00
SYRE cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -16000.00
SYRE balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 0.00
SYRE cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 3035000.00
SYRE cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 84555000.00
SYRE income_statement (annual, 2023-12-31) — Net Income: -338790000.00
SYRE income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -338790000.00
SYRE income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -338790000.00
SYRE income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -338790000.00
SYRE income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -338790000.00
SYRE cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -338790000.00
SYRE income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -338790000.00
SYRE cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: 15000000.00
SYRE income_statement (annual, 2023-12-31) — Net Interest Income: 6147000.00
SYRE cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: -126903000.00
SYRE cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -16000.00
SYRE cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -16000.00
SYRE income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 6147000.00
SYRE cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -5802000.00
SYRE balance_sheet (annual, 2023-12-31) — Net PPE: 0.00
SYRE cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: 475000.00
SYRE cash_flow (annual, 2023-12-31) — Net Preferred Stock Issuance: 281919000.00
SYRE balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 184016000.00
SYRE balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Non Current Deferred Revenue: 0.00
SYRE income_statement (annual, 2023-12-31) — Normalized EBITDA: 69449000.00
SYRE income_statement (annual, 2023-12-31) — Normalized Income: -141536137.99
SYRE cash_flow (annual, 2023-12-31) — Operating Cash Flow: -99910000.00
SYRE cash_flow (annual, 2023-12-31) — Operating Gains Losses: 198184000.00
SYRE income_statement (annual, 2023-12-31) — Operating Income: -128564000.00
SYRE income_statement (annual, 2023-12-31) — Operating Revenue: 886000.00
SYRE balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 36057109.00
SYRE balance_sheet (annual, 2023-12-31) — Other Current Assets: 2251000.00
SYRE balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 1878000.00
SYRE balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: 302000.00
SYRE income_statement (annual, 2023-12-31) — Other Gand A: 39946000.00
SYRE income_statement (annual, 2023-12-31) — Other Income Expense: -216399000.00
SYRE cash_flow (annual, 2023-12-31) — Other Non Cash Items: 19221000.00
SYRE balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 331000.00
SYRE balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 41310000.00
SYRE income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: -19130000.00
SYRE balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 150384000.00
SYRE income_statement (annual, 2023-12-31) — Other Special Charges: 130188000.00
SYRE balance_sheet (annual, 2023-12-31) — Payables: 17480000.00
SYRE balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 26046000.00
SYRE balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 4054000.00
SYRE balance_sheet (annual, 2023-12-31) — Preferred Securities Outside Stock Equity: 84555000.00
SYRE balance_sheet (annual, 2023-12-31) — Preferred Stock: 184927000.00
SYRE income_statement (annual, 2023-12-31) — Preferred Stock Dividends: 243907000.00
SYRE balance_sheet (annual, 2023-12-31) — Preferred Stock Equity: 184927000.00
SYRE cash_flow (annual, 2023-12-31) — Preferred Stock Issuance: 281919000.00
SYRE income_statement (annual, 2023-12-31) — Pretax Income: -338816000.00
SYRE cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 405000.00
SYRE balance_sheet (annual, 2023-12-31) — Properties: 0.00
SYRE cash_flow (annual, 2023-12-31) — Purchase Of Investment: -166803000.00
SYRE cash_flow (annual, 2023-12-31) — Purchase Of PPE: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Receivables: 0.00
SYRE income_statement (annual, 2023-12-31) — Reconciled Depreciation: 744000.00
SYRE cash_flow (annual, 2023-12-31) — Repayment Of Debt: -16000.00
SYRE income_statement (annual, 2023-12-31) — Research And Development: 89504000.00
SYRE balance_sheet (annual, 2023-12-31) — Retained Earnings: -764414000.00
SYRE cash_flow (annual, 2023-12-31) — Sale Of Business: 3035000.00
SYRE cash_flow (annual, 2023-12-31) — Sale Of Intangibles: 15000000.00
SYRE cash_flow (annual, 2023-12-31) — Sale Of Investment: 39900000.00
SYRE cash_flow (annual, 2023-12-31) — Sale Of PPE: 475000.00
SYRE income_statement (annual, 2023-12-31) — Selling General And Administration: 39946000.00
SYRE balance_sheet (annual, 2023-12-31) — Share Issued: 36057109.00
SYRE income_statement (annual, 2023-12-31) — Special Income Charges: -113739000.00
SYRE cash_flow (annual, 2023-12-31) — Stock Based Compensation: 25675000.00
SYRE balance_sheet (annual, 2023-12-31) — Stockholders Equity: 184016000.00
SYRE balance_sheet (annual, 2023-12-31) — Tangible Book Value: -911000.00
SYRE income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -15137.99
SYRE income_statement (annual, 2023-12-31) — Tax Provision: -26000.00
SYRE income_statement (annual, 2023-12-31) — Tax Rate For Calcs:
SYRE balance_sheet (annual, 2023-12-31) — Total Assets: 341859000.00
SYRE balance_sheet (annual, 2023-12-31) — Total Capitalization: 184016000.00
SYRE balance_sheet (annual, 2023-12-31) — Total Debt: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 184016000.00
SYRE income_statement (annual, 2023-12-31) — Total Expenses: 129450000.00
SYRE balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 157843000.00
SYRE balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 331000.00
SYRE balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 125865000.00
SYRE income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -242303000.00
SYRE income_statement (annual, 2023-12-31) — Total Unusual Items: -197269000.00
SYRE income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -197269000.00
SYRE balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 0.00
SYRE balance_sheet (annual, 2023-12-31) — Working Capital: 309550000.00
SYRE cash_flow (quarterly, 2024-09-30) — Asset Impairment Charge: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Change In Other Current Liabilities: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Change In Receivables: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Depreciation: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Depreciation Amortization Depletion: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Depreciation And Amortization: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Long Term Debt Payments: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Net Business Purchase And Sale: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Net Issuance Payments Of Debt: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Net Long Term Debt Issuance: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Net PPE Purchase And Sale: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Net Preferred Stock Issuance: 168850000.00
SYRE balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 10000.00
SYRE balance_sheet (quarterly, 2024-09-30) — Preferred Securities Outside Stock Equity: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Preferred Stock Issuance: 168850000.00
SYRE income_statement (quarterly, 2024-09-30) — Reconciled Depreciation: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Repayment Of Debt: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Sale Of Business: 0.00
SYRE cash_flow (quarterly, 2024-09-30) — Sale Of PPE: 0.00
SYRE income_statement (annual, 2024-12-31) — +Operating Expense: 208566000.00
SYRE income_statement (annual, 2024-12-31) — +Total Revenue: 0.00
SYRE balance_sheet (annual, 2024-12-31) — Accounts Payable: 666000.00
SYRE balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 1334223000.00
SYRE cash_flow (annual, 2024-12-31) — Amortization Of Securities: -11404000.00
SYRE cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Asset Impairment Charge: 0.00
SYRE income_statement (annual, 2024-12-31) — Basic Average Shares: 47027638.00
SYRE income_statement (annual, 2024-12-31) — Basic EPS: -3.18
SYRE cash_flow (annual, 2024-12-31) — Beginning Cash Position: 189215000.00
SYRE balance_sheet (annual, 2024-12-31) — Capital Stock: 155833000.00
SYRE balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 89423000.00
SYRE balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 603088000.00
SYRE cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 410906000.00
SYRE cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -353285000.00
SYRE cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -157410000.00
SYRE cash_flow (annual, 2024-12-31) — Change In Account Payable: -16211000.00
SYRE cash_flow (annual, 2024-12-31) — Change In Accrued Expense: 14609000.00
SYRE cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Change In Other Current Liabilities: 0.00
SYRE cash_flow (annual, 2024-12-31) — Change In Payable: -16211000.00
SYRE cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -1602000.00
SYRE cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: -2932000.00
SYRE cash_flow (quarterly, 2024-12-31) — Change In Prepaid Assets: 1273000.00
SYRE cash_flow (annual, 2024-12-31) — Change In Receivables: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Change In Receivables: 0.00
SYRE cash_flow (annual, 2024-12-31) — Change In Working Capital: -4534000.00
SYRE cash_flow (annual, 2024-12-31) — Changes In Cash: -99789000.00
SYRE balance_sheet (annual, 2024-12-31) — Common Stock: 13000.00
SYRE balance_sheet (annual, 2024-12-31) — Common Stock Equity: 361984000.00
SYRE cash_flow (annual, 2024-12-31) — Common Stock Issuance: 236381000.00
SYRE balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 21522000.00
SYRE balance_sheet (annual, 2024-12-31) — Current Assets: 608474000.00
SYRE balance_sheet (annual, 2024-12-31) — Current Liabilities: 54060000.00
SYRE cash_flow (annual, 2024-12-31) — Depreciation: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Depreciation: 0.00
SYRE cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Depreciation Amortization Depletion: 0.00
SYRE cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Depreciation And Amortization: 0.00
SYRE income_statement (annual, 2024-12-31) — Diluted Average Shares: 47027638.00
SYRE income_statement (annual, 2024-12-31) — Diluted EPS: -3.18
SYRE income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -208018000.00
SYRE balance_sheet (annual, 2024-12-31) — Dueto Related Parties Current: 603000.00
SYRE income_statement (annual, 2024-12-31) — EBIT: -208566000.00
SYRE income_statement (annual, 2024-12-31) — EBITDA: -208566000.00
SYRE cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -3000.00
SYRE cash_flow (quarterly, 2024-12-31) — Effect Of Exchange Rate Changes: -15000.00
SYRE cash_flow (annual, 2024-12-31) — End Cash Position: 89423000.00
SYRE cash_flow (annual, 2024-12-31) — Financing Cash Flow: 410906000.00
SYRE cash_flow (annual, 2024-12-31) — Free Cash Flow: -157410000.00
SYRE cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: 0.00
SYRE income_statement (annual, 2024-12-31) — Gain On Sale Of Ppe: 0.00
SYRE balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 180000.00
SYRE income_statement (annual, 2024-12-31) — General And Administrative Expense: 45776000.00
SYRE income_statement (annual, 2024-12-31) — Interest Income: 21312000.00
SYRE income_statement (annual, 2024-12-31) — Interest Income Non Operating: 21312000.00
SYRE cash_flow (annual, 2024-12-31) — Interest Received Cfo: 1283000.00
SYRE cash_flow (quarterly, 2024-12-31) — Interest Received Cfo: 702000.00
SYRE balance_sheet (annual, 2024-12-31) — Invested Capital: 361984000.00
SYRE cash_flow (annual, 2024-12-31) — Investing Cash Flow: -353285000.00
SYRE cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 405231000.00
SYRE cash_flow (annual, 2024-12-31) — Long Term Debt Payments: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Long Term Debt Payments: 0.00
SYRE cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Net Business Purchase And Sale: 0.00
SYRE cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 236381000.00
SYRE income_statement (annual, 2024-12-31) — Net Income: -208018000.00
SYRE income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -208018000.00
SYRE income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -208018000.00
SYRE income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -208018000.00
SYRE income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -208018000.00
SYRE cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -208018000.00
SYRE income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -208018000.00
SYRE cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: 0.00
SYRE income_statement (annual, 2024-12-31) — Net Interest Income: 21312000.00
SYRE cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: -353285000.00
SYRE cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Net Issuance Payments Of Debt: 0.00
SYRE cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Net Long Term Debt Issuance: 0.00
SYRE income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 21312000.00
SYRE cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -1836000.00
SYRE cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Net PPE Purchase And Sale: 0.00
SYRE cash_flow (annual, 2024-12-31) — Net Preferred Stock Issuance: 168850000.00
SYRE cash_flow (quarterly, 2024-12-31) — Net Preferred Stock Issuance: 0.00
SYRE balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 517804000.00
SYRE income_statement (annual, 2024-12-31) — Normalized EBITDA: -208566000.00